Skip to main content

Free Content Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in China

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

Objective  In China, Chloroquine (CQ) and sulfadoxine–pyrimethamine (SP) were abandoned for the treatment of falciparum malaria 20 years ago due to resistance. Subsequent field studies showed a trend of declining CQ and SP resistance in the country. The main purpose of this study was to analyse the molecular markers of antimalarial resistance and thereby to assess the possibility of reintroduction of CQ or SP for falciparum malaria treatment.

Keywords: Plasmodium falciparum; Resistencia a medicamentos; drug resistance; polimorfismos de nucleótidos simples; polymerase chain reaction; polymorphisme de nucléotide simple; reacción en cadena de la polimerasa; réaction en chaîne de la polymérase; résistance aux médicaments; single nucleotide polymorphism

Language: English

Document Type: Research Article

DOI: https://doi.org/10.1111/j.1365-3156.2009.02342.x

Affiliations: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, WHO Collaborating Center for Malaria, Schistosomiasis and Filariasis, Shanghai, China

Publication date: 2009-10-01

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more